Research programme: DNA repair enzyme inhibitors - KuDOS

Drug Profile

Research programme: DNA repair enzyme inhibitors - KuDOS

Alternative Names: 1,3-dipropyl-7-methylxanthine; DNA repair enzyme inhibitors research programme - KuDOS; DPMX; KU 55933; KU-0060648; KU-0063794

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KuDOS Pharmaceuticals
  • Developer Galapagos NV; KuDOS Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
  • 06 Apr 2011 Pharmacodynamics data from preclinical trials in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR-2011)
  • 19 Nov 2009 Pharmacodynamics data from in vitro & preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top